Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $25,400.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Trading Down 4.4 %

Shares of GYRE opened at $12.10 on Thursday. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $27.45. The stock has a fifty day moving average of $12.64 and a 200-day moving average of $12.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GYRE. Barclays PLC raised its position in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares during the period. State Street Corp lifted its stake in shares of Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after buying an additional 8,412 shares in the last quarter. FMR LLC bought a new position in Gyre Therapeutics in the 3rd quarter valued at about $47,000. Finally, Advantage Alpha Capital Partners LP bought a new position in shares of Gyre Therapeutics in the third quarter valued at approximately $334,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.